NASDAQ · Biotechnology

Lakewood-Amedex Biotherapeutics Inc. (LABT) Stock

$0.78 -1.24% NASDAQ: LABT Healthcare

Valuation

MetricValue
Price$0.78
Market Cap$1.37M
P/E Ratio-0.17
P/B Ratio0.55
P/S Ratio0.00
EPS (TTM)$-3.26
52-Week High$98.20
52-Week Low$0.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE200.00%
ROA-148.13%
ROCE-167.83%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio7.70

Annual Financials (USD)

Metric202320242025
Revenue$0$0$0
Operating Profit$-9.0M$-4.0M$-4.0M
Net Profit$-8.0M$-5.0M$-4.0M
EPS$-11.84$-6.94$-2.76
Op Margin———

Balance Sheet (USD)

Metric202320242025
Total Assets——$0
Total Liabilities——$2.0M
Cash——$0
Borrowings$0$0$2.0M

Latest News

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria PR Newswire · Jul 22, 2026 Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel PR Newswire · Jul 15, 2026 CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics Zacks Small Cap Research · Jul 13, 2026 Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance PR Newswire · Jul 7, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric202320242025
Operating Cash Flow——$-2.0M
Investing Cash Flow——$0
Financing Cash Flow——$0
Net Cash Flow——$0
Free Cash Flow$0$0$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.06
FCF Yield-119.23%
Quick Ratio7.70
Interest Coverage-58.40
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held48.67%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Blue Trust, Inc.112026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. is led by CEO Kelvin Cooper, headquartered in US, publicly traded since 2026.

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock trades at $0.78 with a market capitalization of $1.37M. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of 0.55, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.78 and $98.20, and currently trades 99.2% below its 52-week high.

On profitability, Lakewood-Amedex Biotherapeutics Inc. generates a return on equity (ROE) of 200.00% — well above the market average, a sign of a high-quality business, return on capital employed of -167.83%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides